Clinical Research Division, Fred Hutch
Dr. Shailender Bhatia aims to improve outcomes for people with kidney cancers and skin cancers, especially melanoma and Merkel cell carcinoma. He leads clinical trials of new immunotherapies and targeted, less-toxic therapies for patients with these diseases.
Dr. Bhatia’s research efforts are mostly focused on clinical trials that aim at improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma). He is especially interested in those novel therapeutic approaches that stimulate the immune system against cancer and those that target therapy to the tumors in order to spare unnecessary toxicity.